Ascletis Pharma Inc banner

Ascletis Pharma Inc
HKEX:1672

Watchlist Manager
Ascletis Pharma Inc Logo
Ascletis Pharma Inc
HKEX:1672
Watchlist
Price: 14.61 HKD 2.89% Market Closed
Market Cap: HK$14.5B

Ascletis Pharma Inc
Investor Relations

Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

Show more
Loading
1672
Hang Seng (Hong Kong)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Jinzi Jason Wu Ph.D.
Founder, Chairman & CEO
No Bio Available
Ms. Hejingdao Wu
Senior VP of Operations & Executive Director
No Bio Available
Ms. Yuemei Yan
Senior Vice President of Clinical Development Operations
No Bio Available
Dr. Kristjan Sigurdur Gudmundsson
Senior Consultant & Head of Discovery
No Bio Available
Dr. George Zhengzhi Hill
Senior Consultant & Chief Medical Advisor
No Bio Available
Mr. John P. Gargiulo M.B.A.
Chief Business Officer
No Bio Available
Mr. Ming Fai Chung CPA
Company Secretary
No Bio Available

Contacts

Address
ZHEJIANG
Hangzhou
12F, Tower D, Hangzhou Bay Information Port, No.198, Qidi Road, Xiaoshan District
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett